The combination of IL-17A and PD-1 blockade exhibited efficacy in CRC tumors, resulting in increased presence of cytotoxic T lymphocytes and decreased presence of myeloid-derived suppressor cells within the tumors [127]. This evidence concerns the gene PDCD1 and colorectal carcinoma.